MedTrace Logo

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

NCT02078427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 951

Last updated 2024-06-17

No results posted yet for this study

Summary

The purpose of the study is to document the natural history of hemophilia A disease and long-term outcomes in terms of effectiveness, safety and quality of life in participants receiving Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM) or Antihemophilic Factor (Recombinant) - Pegylated (rAHF-PEG) in routine clinical practice

Conditions

Interventions

BIOLOGICAL

ADVATE

Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

BIOLOGICAL

ADYNOVI

Antihemophilic Factor (Recombinant) Pegylated

Sponsors & Collaborators

  • Baxalta Innovations GmbH, now part of Shire

    collaborator INDUSTRY

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-28
Primary Completion
2024-01-16
Completion
2024-01-16
FDA Drug
Yes

Countries

  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • China
  • Colombia
  • Czechia
  • Denmark
  • France
  • Greece
  • Hungary
  • Italy
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078427 on ClinicalTrials.gov